BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Mario F, Aragona G, Bò ND, Ingegnoli A, Cavestro GM, Moussa AM, Iori V, Leandro G, Pilotto A, Franzè A. Use of lactoferrin for Helicobacter pylori eradication. Preliminary results. J Clin Gastroenterol. 2003;36:396-398. [PMID: 12702979 DOI: 10.1097/00004836-200305000-00006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang LS, Echeveste CE, Yu J, Huang YW, Lechner J, Mei L, Sanvanson P, Yearsley M, Wang CK, Stoner G. Can Natural Products Suppress Resistant Helicobacter pylori to Fight Against Gastric Diseases in Humans? eFood 2020;1:53-60. [PMID: 34308385 DOI: 10.2991/efood.k.200211.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Kuhara T, Yamauchi K, Tamura Y, Okamura H. Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J Interferon Cytokine Res 2006;26:489-99. [PMID: 16800788 DOI: 10.1089/jir.2006.26.489] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
3 Di Mario F, Cavallaro LG, Scarpignato C. ‘Rescue’ therapies for the management of Helicobacter pylori infection. Dig Dis. 2006;24:113-130. [PMID: 16699270 DOI: 10.1159/000090315] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
4 Zullo A, Hassan C, Campo SM, Morini S. Evolving therapy for Helicobacter pylori infection. Expert Opinion on Therapeutic Patents 2005;14:1453-64. [DOI: 10.1517/13543776.14.10.1453] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
5 Morgner A, Labenz J, Miehlke S. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 2006;15:995-1016. [PMID: 16916269 DOI: 10.1517/13543784.15.9.995] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
6 Zullo A, De Francesco V, Scaccianoce G, Hassan C, Panarese A, Piglionica D, Panella C, Morini S, Ierardi E. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study. Dig Liver Dis. 2005;37:496-500. [PMID: 15975536 DOI: 10.1016/j.dld.2005.01.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
7 Abdou H, Marichatou H, Beckers J, Dufrasne I, Hornick J. Effect of bovine colostrum administration on plasma protein profile, growth, and survival in Red kid. Small Ruminant Research 2014;117:158-64. [DOI: 10.1016/j.smallrumres.2013.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Zou J, Dong J, Yu XF. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy. Helicobacter. 2009;14:119-127. [PMID: 19298339 DOI: 10.1111/j.1523-5378.2009.00666.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
9 Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337.pub2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
10 Takeuchi H, Trang VT, Morimoto N, Nishida Y, Matsumura Y, Sugiura T. Natural products and food components with anti-Helicobacter pylori activities. World J Gastroenterol 2014; 20(27): 8971-8978 [PMID: 25083070 DOI: 10.3748/wjg.v20.i27.8971] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
11 Talley NJ, Li Z. Helicobacter pylori: testing and treatment. Expert Rev Gastroenterol Hepatol 2007;1:71-9. [PMID: 19072436 DOI: 10.1586/17474124.1.1.71] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
12 Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: A review of current trends. Niger Med J. 2013;54:1-4. [PMID: 23661891 DOI: 10.4103/0300-1652.108884] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
13 Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2009;29:720-730. [PMID: 19183156 DOI: 10.1111/j.1365-2036.2009.03934.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
14 Yuan Y, Wu Q, Cheng G, Liu X, Liu S, Luo J, Zhang A, Bian L, Chen J, Lv J, Dong X, Yang G, Zhu Y, Ma L. Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori. Int J Mol Med 2015;36:363-8. [PMID: 26080893 DOI: 10.3892/ijmm.2015.2251] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
15 Di Mario F, Aragona G, Dal Bó N, Cavallaro L, Marcon V, Olivieri P, Benedetti E, Orzès N, Marin R, Tafner G. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment Pharmacol Ther. 2006;23:1235-1240. [PMID: 16611285 DOI: 10.1111/j.1365-2036.2006.02851.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
16 Shin K, Wakabayashi H, Yamauchi K, Teraguchi S, Tamura Y, Kurokawa M, Shiraki K. Effects of orally administered bovine lactoferrin and lactoperoxidase on influenza virus infection in mice. Journal of Medical Microbiology 2005;54:717-23. [DOI: 10.1099/jmm.0.46018-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
17 Jodlowski TZ, Lam S, Ashby CR. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother. 2008;42:1621-1639. [PMID: 18845620 DOI: 10.1345/aph.1l234] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
18 Mueller A, Merrell DS, Grimm J, Falkow S. Profiling of microdissected gastric epithelial cells reveals a cell type-specific response to Helicobacter pylori infection. Gastroenterology 2004;127:1446-62. [PMID: 15521014 DOI: 10.1053/j.gastro.2004.08.054] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
19 Zou J, Dong J, Yu XF. Meta-analysis on the efficacy of lactoferrin supplementation combined with standard treatment during Helicobacter pylori eradication therapy. Shijie Huaren Xiaohua Zazhi 2009; 17(9): 918-926 [DOI: 10.11569/wcjd.v17.i9.918] [Reference Citation Analysis]
20 McLoughlin R, Racz I, Buckley M, O'Connor HJ, O'Morain C. Therapy of Helicobacter pylori. Helicobacter. 2004;9 Suppl 1:42-48. [PMID: 15347305 DOI: 10.1111/j.1083-4389.2004.00251.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
21 Vilaichone RK, Mahachai V, Graham DY. Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am. 2006;35:229-247. [PMID: 16880064 DOI: 10.1016/j.gtc.2006.03.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
22 Meyer JM. Use of Lactoferrin for Helicobacter pylori Eradication: . Journal of Clinical Gastroenterology 2003;36:384-6. [DOI: 10.1097/00004836-200305000-00003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
23 Jones KR, Cha JH, Merrell DS. Who’s Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. Curr Drug ther. 2008;3:190-203. [PMID: 21765819 DOI: 10.2174/157488508785747899] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
24 Zullo A, De Francesco V, Scaccianoce G, Manes G, Efrati C, Hassan C, Maconi G, Piglionica D, Cannaviello C, Panella C. Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study. Dig Liver Dis. 2007;39:806-810. [PMID: 17644057 DOI: 10.1016/j.dld.2007.05.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
25 Krissansen GW. Emerging health properties of whey proteins and their clinical implications. J Am Coll Nutr. 2007;26:713S-723S. [PMID: 18187438 DOI: 10.1080/07315724.2007.10719652] [Cited by in Crossref: 155] [Cited by in F6Publishing: 121] [Article Influence: 11.1] [Reference Citation Analysis]
26 Liu XF, Cheng GX, Yuan YP, Zhang AM, Luo J, Liu SG, Chen JQ, Dong XQ, Zhang L, Ma LQ. Effect of recombinant human lactoferrin treatment on mRNA expression of vacuolating cytotoxin A and content of tumor necrosis factor-α in gastric tissue of mice with Helicobacter pylori-associated gastritis. Shijie Huaren Xiaohua Zazhi 2015; 23(18): 2860-2867 [DOI: 10.11569/wcjd.v23.i18.2860] [Reference Citation Analysis]